MarketCap
Facebook
X
Telegram
Dyadic International Net Debt | DYAI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Dyadic International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -6.42 M | -6.38 M | - | - | -20.6 M | -4.82 M | -2.39 M | -5.79 M | -6.89 M | -68.6 M | 5.64 M | -649 K | 4.43 M | 4.73 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.64 M | -68.6 M | -8.98 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
612 M | - | - | - |  Russia |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
-107 M | - | - | $ 621 M |  Britain |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-13.8 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Revolution Medicines
RVMD
|
-225 M | $ 207.32 | 0.24 % | $ 39.4 B |  USA |
 |
Rhythm Pharmaceuticals
RYTM
|
47.2 M | $ 101.8 | 0.08 % | $ 6.62 B | USA |
|
Rezolute
RZLT
|
-92.5 M | $ 4.4 | 0.88 % | $ 334 M | USA |
 |
Sana Biotechnology
SANA
|
6.99 M | $ 3.45 | 0.77 % | $ 874 M | USA |
 |
Seer
SEER
|
-23.6 M | $ 1.95 | 0.26 % | $ 108 M | USA |
 |
Precigen
PGEN
|
64.1 M | $ 6.87 | 0.14 % | $ 2.15 B | USA |
 |
SIGA Technologies
SIGA
|
-154 M | $ 3.2 | 1.86 % | $ 229 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-152 M | $ 19.94 | 0.05 % | $ 1.73 B | USA |
 |
Soligenix
SNGX
|
-7.58 M | $ 0.38 | 1.18 % | $ 1.97 M | USA |
 |
Spruce Biosciences
SPRB
|
-38.3 M | $ 59.09 | 2.0 % | $ 45.3 M | USA |
 |
Sarepta Therapeutics
SRPT
|
38.9 M | $ 20.94 | 0.04 % | $ 2.1 B | USA |
 |
Stoke Therapeutics
STOK
|
-80.1 M | $ 30.05 | 0.81 % | $ 1.78 B | USA |
 |
Sutro Biopharma
STRO
|
-42.5 M | $ 19.1 | 0.34 % | $ 162 M | USA |
 |
Shattuck Labs
STTK
|
-51.8 M | $ 6.5 | 0.29 % | $ 452 M | USA |
 |
Supernus Pharmaceuticals
SUPN
|
-87.5 M | $ 42.43 | 0.23 % | $ 2.4 B | USA |
 |
Savara
SVRA
|
-3.27 M | $ 5.53 | 2.98 % | $ 1.23 B | USA |
 |
China SXT Pharmaceuticals
SXTC
|
-27.5 M | $ 2.24 | 0.45 % | $ 1.52 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
4.46 T | $ 18.32 | 1.49 % | $ 28.9 B |  Japan |
 |
Bio-Techne Corporation
TECH
|
-49.8 M | $ 72.31 | 0.01 % | $ 11.3 B | USA |
 |
Tenax Therapeutics
TENX
|
-2.06 M | $ 1.98 | 2.06 % | $ 77.7 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
-2.98 B | $ 36.76 | 1.21 % | $ 42.1 B | Israel |
 |
TG Therapeutics
TGTX
|
168 M | $ 55.74 | 0.58 % | $ 8.04 B | USA |
 |
Trevi Therapeutics
TRVI
|
-18.2 M | $ 16.82 | 1.17 % | $ 2.27 B | USA |
 |
Taysha Gene Therapies
TSHA
|
-268 M | $ 5.48 | 0.54 % | $ 1.75 B | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-10 M | $ 69.37 | 0.35 % | $ 193 M | Israel |
 |
UroGen Pharma Ltd.
URGN
|
11.9 M | $ 43.82 | 0.02 % | $ 2.11 B | Israel |
 |
United Therapeutics Corporation
UTHR
|
112 M | $ 497.97 | 2.12 % | $ 22.1 B | USA |
 |
Spero Therapeutics
SPRO
|
-37.4 M | $ 1.19 | 0.41 % | $ 66.7 M | USA |
 |
Scholar Rock Holding Corporation
SRRK
|
-218 M | $ 57.42 | 3.78 % | $ 6.59 B | USA |
 |
Jounce Therapeutics
JNCE
|
-141 M | - | - | $ 98.4 M | USA |
 |
NextCure
NXTC
|
-20.8 M | $ 8.42 | 7.67 % | $ 23.9 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
-15 M | $ 5.26 | 0.75 % | $ 56 M | USA |
 |
Viridian Therapeutics
VRDN
|
-210 M | $ 23.17 | 1.09 % | $ 2.36 B | USA |
 |
Zosano Pharma Corporation
ZSAN
|
-6.36 M | - | 7.23 % | $ 2.72 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
-4.9 B | $ 528.9 | 0.22 % | $ 135 B | USA |
 |
Verastem
VSTM
|
-47.1 M | $ 8.08 | 0.55 % | $ 560 M | USA |
 |
vTv Therapeutics
VTVT
|
-9.11 M | $ 32.79 | 0.03 % | $ 130 M | USA |
 |
Voyager Therapeutics
VYGR
|
-28.8 M | $ 3.4 | 3.85 % | $ 200 M | USA |
 |
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
-584 M | $ 4.91 | 1.03 % | $ 828 M | Singapore |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-206 M | $ 13.16 | 0.15 % | $ 112 M | USA |
 |
Xenetic Biosciences
XBIO
|
-11.5 M | $ 4.28 | 0.86 % | $ 7.28 M | USA |
|
XBiotech
XBIT
|
-237 M | $ 2.18 | 0.23 % | $ 66.5 M | USA |
 |
Exicure
XCUR
|
-6.57 M | $ 1.41 | 12.8 % | $ 8.88 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
-191 M | $ 59.55 | 0.18 % | $ 4.72 B |  Canada |
 |
Xeris Pharmaceuticals
XERS
|
116 M | $ 8.48 | 0.12 % | $ 1.36 B | USA |